Download PDF
Thromb Haemost 1985; 54(02): 413-414
DOI: 10.1055/s-0038-1657861
Original Article
Schattauer GmbH Stuttgart

Plasminogen Activation in Diabetes Mellitus: Normalization of Blood Sugar Levels Improves Impaired Enzyme Kinetics In Vitro

Margarethe Geiger
The Laboratory for Clinical-Experimental Physiology, Department of Medical Physiology, University of Vienna, Austria
,
Bernd R Binder
The Laboratory for Clinical-Experimental Physiology, Department of Medical Physiology, University of Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received 06 February 1985

Accepted 24 April 1985

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We have demonstrated previously that fibrin enhanced plasmin formation by the vascular plasminogen activator was significantly impaired, when components isolated from the plasma of three uncontrolled diabetic patients (type I) were used to study plasminogen activation in vitro. In the present study it can be demonstrated that functional properties of the vascular plasminogen activators as well as of the plasminogens from the same three diabetic patients are significantly improved after normalization of blood sugar levels and improvement of HbAlc values. Most pronounced the Km of diabetic vascular plasminogen activator in the presence of fibrin returned to normal values, and for diabetic plasminogen the prolonged lag period until maximal plasmin formation occurred was shortened to almost control values. From these data we conclude that the observed abnormalities of in vitro fibrinolysis are not primarily associated with the diabetic disease, but might be secondary to metabolic disorders caused by diabetes.

Keywords

Plasminogen activation - Diabetes - Enzyme kinetics - Tissue plasminogen activator - Fibrinolysis
 

  • References

  • 1 Geiger M, Binder BR. Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors. J Biol Chem 1984; 259: 2976-2981
    PubMedGoogle Scholar
  • 2 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 3 Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-469
    CrossrefPubMedGoogle Scholar
  • 4 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
    PubMedGoogle Scholar
  • 5 Deutsch DG, Mertz ET. Plasminogen. Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 6 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 7 Morrissey JH. Silverstain for proteins in polyacrylamide gels: A modified procedure with enhanced uniform sensitivity. Anal Biochem 1981; 117: 307-310
    CrossrefPubMedGoogle Scholar
  • 8 Binder BR, Spragg J, Austen KF. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 1979; 254: 1998-2003
    PubMedGoogle Scholar
  • 9 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 10 Norrman B, Wallen P, Ranby M. Tissue plasminogen activator: Plasminogen activation with special reference to early events. Haemostasis 1984; 14/01 (14) Abstr. 17
    PubMedGoogle Scholar
  • 11 Colwell YA, Halushka PV, Sarji KE, Lopes-Virella MF, Sagel J. Vascular disease in diabetes. Pathophysiological Mechanisms and Therapy. Arch Intern Med 1979; 139: 225-230
    CrossrefPubMedGoogle Scholar